Limits...
Cognitive impairment and Alzheimer's disease: Links with oxidative stress and cholesterol metabolism.

Sekler A, Jiménez JM, Rojo L, Pastene E, Fuentes P, Slachevsky A, Maccioni RB - Neuropsychiatr Dis Treat (2008)

Bottom Line: Oxidative stress has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis.No significant differences were observed when the cholesterol parameters (low-, high-density lipoprotein, total cholesterol) of the AD group were compared with normal controls.Significant differences in AOC were found between subgroups.

View Article: PubMed Central - PubMed

Affiliation: Center of Cognitive Neurosciences, International Center for Biomedicine (ICC), Providencia 455, Dept. 303, Providencia, Santiago, Chile. cbb@uchile.cl

ABSTRACT
Oxidative stress has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis. We carried out an in-depth study of cognitive impairment and its relationships with oxidative stress markers such as ferric-reducing ability of plasma (FRAP), plasma malondialdehyde and total antioxidative capacity (TAC), as well as cholesterol parameters, in two subsets of subjects, AD patients (n = 59) and a control group of neurologically normal subjects (n = 29), attending the University Hospital Salvador in Santiago, Chile. Cognitive impairment was assessed by a set of neuropsychological tests (Mini-Mental State Examination, Boston Naming Test, Ideomotor Praxia by imitation, Semantic Verbal Fluency of animals or words with initial A, Test of Memory Alteration, Frontal Assessment Battery), while the levels of those oxidative stress markers and cholesterol metabolism parameters were determined according with standard bioassays in fresh plasma samples of the two subgroups of patients. No significant differences were observed when the cholesterol parameters (low-, high-density lipoprotein, total cholesterol) of the AD group were compared with normal controls. Interestingly, a correlation was evidenced when the levels of cognitive impairment were analyzed with respect to the plasma antioxidant capacity (AOC) of patients. In this context, the subset of subjects exhibiting cognitive impairment were divided into two subgroups according with their Global Dementia Scale performance: a subgroup with mild AD and a subgroup with moderate to severe AD. Significant differences in AOC were found between subgroups. The different correlations between cognitive impairment of subgroups of subjects with the oxidative stress profile are discussed in the context of AD pathogenesis.

No MeSH data available.


Related in: MedlinePlus

Ferric reducing ability of plasma (eq. Fe(II) μM) of patients with Alzheimer’s disease at different stages of the disease, as evaluated by GDS. Other details in Methods. The number of subjects in every group (n) was: n = 23 in the mild AD (GDS = 3–4);n = 24 in the moderate AD (GDS 5), and n = 12 for severe AD; n = 29 for the control group.Note: * Significant differences (p < 0.05) between control subgroup (or mild AD) vs moderate or severe AD. One-way ANOVA and Bonferroni’s comparison test wre used to assess differences in mean values.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2536538&req=5

fig1: Ferric reducing ability of plasma (eq. Fe(II) μM) of patients with Alzheimer’s disease at different stages of the disease, as evaluated by GDS. Other details in Methods. The number of subjects in every group (n) was: n = 23 in the mild AD (GDS = 3–4);n = 24 in the moderate AD (GDS 5), and n = 12 for severe AD; n = 29 for the control group.Note: * Significant differences (p < 0.05) between control subgroup (or mild AD) vs moderate or severe AD. One-way ANOVA and Bonferroni’s comparison test wre used to assess differences in mean values.

Mentions: The oxidative stress biomarkers analyzed in this article are summarized in Table 3. In all the assays applied, no statistical differences were observed between the AD subset and the control subjects. However, when subjects exhibiting cognitive impairment were divided into subgroups according with their GDS performance score, significant differences in FRAP were found between the controls and the moderate and severe AD subgroups, and between mild and moderate/severe AD (Figure 1).


Cognitive impairment and Alzheimer's disease: Links with oxidative stress and cholesterol metabolism.

Sekler A, Jiménez JM, Rojo L, Pastene E, Fuentes P, Slachevsky A, Maccioni RB - Neuropsychiatr Dis Treat (2008)

Ferric reducing ability of plasma (eq. Fe(II) μM) of patients with Alzheimer’s disease at different stages of the disease, as evaluated by GDS. Other details in Methods. The number of subjects in every group (n) was: n = 23 in the mild AD (GDS = 3–4);n = 24 in the moderate AD (GDS 5), and n = 12 for severe AD; n = 29 for the control group.Note: * Significant differences (p < 0.05) between control subgroup (or mild AD) vs moderate or severe AD. One-way ANOVA and Bonferroni’s comparison test wre used to assess differences in mean values.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2536538&req=5

fig1: Ferric reducing ability of plasma (eq. Fe(II) μM) of patients with Alzheimer’s disease at different stages of the disease, as evaluated by GDS. Other details in Methods. The number of subjects in every group (n) was: n = 23 in the mild AD (GDS = 3–4);n = 24 in the moderate AD (GDS 5), and n = 12 for severe AD; n = 29 for the control group.Note: * Significant differences (p < 0.05) between control subgroup (or mild AD) vs moderate or severe AD. One-way ANOVA and Bonferroni’s comparison test wre used to assess differences in mean values.
Mentions: The oxidative stress biomarkers analyzed in this article are summarized in Table 3. In all the assays applied, no statistical differences were observed between the AD subset and the control subjects. However, when subjects exhibiting cognitive impairment were divided into subgroups according with their GDS performance score, significant differences in FRAP were found between the controls and the moderate and severe AD subgroups, and between mild and moderate/severe AD (Figure 1).

Bottom Line: Oxidative stress has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis.No significant differences were observed when the cholesterol parameters (low-, high-density lipoprotein, total cholesterol) of the AD group were compared with normal controls.Significant differences in AOC were found between subgroups.

View Article: PubMed Central - PubMed

Affiliation: Center of Cognitive Neurosciences, International Center for Biomedicine (ICC), Providencia 455, Dept. 303, Providencia, Santiago, Chile. cbb@uchile.cl

ABSTRACT
Oxidative stress has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis. We carried out an in-depth study of cognitive impairment and its relationships with oxidative stress markers such as ferric-reducing ability of plasma (FRAP), plasma malondialdehyde and total antioxidative capacity (TAC), as well as cholesterol parameters, in two subsets of subjects, AD patients (n = 59) and a control group of neurologically normal subjects (n = 29), attending the University Hospital Salvador in Santiago, Chile. Cognitive impairment was assessed by a set of neuropsychological tests (Mini-Mental State Examination, Boston Naming Test, Ideomotor Praxia by imitation, Semantic Verbal Fluency of animals or words with initial A, Test of Memory Alteration, Frontal Assessment Battery), while the levels of those oxidative stress markers and cholesterol metabolism parameters were determined according with standard bioassays in fresh plasma samples of the two subgroups of patients. No significant differences were observed when the cholesterol parameters (low-, high-density lipoprotein, total cholesterol) of the AD group were compared with normal controls. Interestingly, a correlation was evidenced when the levels of cognitive impairment were analyzed with respect to the plasma antioxidant capacity (AOC) of patients. In this context, the subset of subjects exhibiting cognitive impairment were divided into two subgroups according with their Global Dementia Scale performance: a subgroup with mild AD and a subgroup with moderate to severe AD. Significant differences in AOC were found between subgroups. The different correlations between cognitive impairment of subgroups of subjects with the oxidative stress profile are discussed in the context of AD pathogenesis.

No MeSH data available.


Related in: MedlinePlus